Skip to main content
Publications
Cheol Lee J, Hung JY, Kim YC, Chang GC, Soo Yoo S, Yang SH, Davis KL, Nagar SP, Taylor A, Yong Lee S, Shih JY. Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan. Asian Pac J Cancer Bio. 2021 May 20;6(2). doi: 10.31557/APJCB.2021.6.2.123-132
Garcia Del Blanco B, Otaegui I, Rodriguez-Palomares JF, Bayes-Genis A, Fernandez-Nofrerias E, Vilalta Del Olmo V, Carrillo X, Ibanez B, Worner F, Casanova J, Pueo E, Gonzalez-Juanatey JR, Lopez-Pais J, Bardaji A, Bonet G, Fuertes M, Rodriguez-Sinovas A, Ruiz-Meana M, Inserte J, Barba I, Gomez-Talavera S, Marti G, Serra B, Bellera N, Ojeda-Ramos M, Cuellar H, Valente F, Carmona MA, Miro-Casas E, Marsal JR, Sambola A, Lidon RM, Baneras J, Elizaga J, Padilla F, Barrabes JA, Hausenloy DJ, Ferreira-Gonzalez I, Garcia-Dorado D. Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI). Basic Res Cardiol. 2021 Jan 25;116(1):4. doi: 10.1007/s00395-021-00842-2